Stockholders Back 100M Share Equity Plan Expansion and Written Consent Change
TVGN sits 84% above its 52-week low of $3.636 on light trading volume (0.1× avg).
Summary
Stockholders approved adding 100 million shares to the 2024 Omnibus Incentive Plan and a charter amendment permitting written consent, with the Certificate of Amendment filed August 26, 2026.
Key Events · Corporate Governance and Compliance · TVGN
-
100M Share Equity Plan Increase Approved
Stockholders approved Amendment No. 2 to the 2024 Omnibus Incentive Plan, increasing the share reserve by 100,000,000 shares to a new Initial Share Limit of 102,800,000 shares, plus an annual increase of up to 5% of outstanding shares.
-
Potential Dilution Exceeds 15x Current Shares
With only 6,416,540 shares outstanding as of the July 23, 2026 record date, the newly authorized 100 million shares represent potential dilution of over 15 times the current share count if fully issued.
-
Written Consent Amendment Filed
The Certificate of Amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on August 26, 2026, permitting stockholder action by written consent in lieu of a meeting, effective immediately.
-
Vote Results Confirm Overwhelming Support
Proposal 3 (Plan Amendment) passed with 5,322,668 votes for and 98,744 against; Proposal 4 (Written Consent) passed with 5,382,051 votes for and 38,005 against, reflecting the controlling shareholder's support.
Analysis · TVGN · Life Sciences
A massive expansion of the equity incentive plan won stockholder approval, adding 100 million shares to the pool — a move that could significantly dilute existing holders if fully utilized. The charter was also amended to allow stockholder action by written consent, streamlining future governance decisions. With only 6.4 million shares outstanding and a market cap near $45 million, the newly authorized shares represent a potential dilution of over 15 times the current share count. The approval follows a proxy filing that had already flagged the plan increase as a 15.6x expansion, and the vote results confirm overwhelming support from the controlling shareholder.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVGN was trading at $6.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.4M. The 52-week trading range was $3.64 to $49.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.